PDF(Pubmed)
Abstract：
UNASSIGNED: Obstruction is a common complication of advanced colorectal cancer. This study was aimed at investigating the safety, efficacy, and feasibility of transcatheter arterial perfusion chemotherapy combined with lipiodol chemoembolization for treating advanced colorectal cancer complicated by obstruction.
UNASSIGNED: This retrospective analysis was conducted using clinical data of patients with advanced colorectal cancer who received arterial infusion chemotherapy combined with lipiodol chemoembolization treatment at our center. Treatment efficacy was evaluated in terms of obstruction-free survival and overall survival, and treatment complications were monitored.
UNASSIGNED: Fifty-four patients with colorectal cancer complicated by obstruction were included. All patients successfully underwent transcatheter arterial infusion combined with lipiodol chemoembolization treatment. The average lipiodol dose administered was 2.62 ± 1.45 ml (0.5-5.5 ml). No serious complications such as perforation or tumor dissemination occurred. The clinical success rate was 83.3% (45/54). One month after treatment, the objective response rate (ORR) and disease control rate (DCR) were 66.67% and 88.9%, respectively. The median obstruction-free survival was 5.0 months. No serious adverse events occurred. As of the last follow-up, 6 patients survived, 44 died, and 4 were lost to follow-up.
UNASSIGNED: Our findings revealed that transcatheter arterial infusion chemotherapy combined with lipiodol chemoembolization is safe and effective for treating advanced colorectal cancer complicated by obstruction. It may serve as a new treatment strategy for patients with advanced colorectal cancer complicated by obstruction.
UNASSIGNED: This retrospective analysis was conducted using clinical data of patients with advanced colorectal cancer who received arterial infusion chemotherapy combined with lipiodol chemoembolization treatment at our center. Treatment efficacy was evaluated in terms of obstruction-free survival and overall survival, and treatment complications were monitored.
UNASSIGNED: Fifty-four patients with colorectal cancer complicated by obstruction were included. All patients successfully underwent transcatheter arterial infusion combined with lipiodol chemoembolization treatment. The average lipiodol dose administered was 2.62 ± 1.45 ml (0.5-5.5 ml). No serious complications such as perforation or tumor dissemination occurred. The clinical success rate was 83.3% (45/54). One month after treatment, the objective response rate (ORR) and disease control rate (DCR) were 66.67% and 88.9%, respectively. The median obstruction-free survival was 5.0 months. No serious adverse events occurred. As of the last follow-up, 6 patients survived, 44 died, and 4 were lost to follow-up.
UNASSIGNED: Our findings revealed that transcatheter arterial infusion chemotherapy combined with lipiodol chemoembolization is safe and effective for treating advanced colorectal cancer complicated by obstruction. It may serve as a new treatment strategy for patients with advanced colorectal cancer complicated by obstruction.
摘要：
■梗阻是晚期结直肠癌的常见并发症。这项研究的目的是调查安全性，功效,经导管动脉灌注化疗联合碘油化疗栓塞治疗晚期结直肠癌合并梗阻的可行性。
■这项回顾性分析是使用在我们中心接受动脉灌注化疗联合碘油化疗栓塞治疗的晚期结直肠癌患者的临床资料进行的。根据无梗阻生存期和总生存期评估治疗效果，监测治疗并发症。
■纳入54例结直肠癌合并梗阻患者。所有患者均成功行经导管动脉灌注联合碘油化疗栓塞治疗。给予的平均碘油剂量为2.62±1.45ml(0.5-5.5ml)。无穿孔、肿瘤播散等严重并发症发生。临床成功率为83.3%(45/54)。治疗后一个月，客观有效率(ORR)和疾病控制率(DCR)分别为66.67%和88.9%,分别。中位无梗阻生存期为5.0个月。无严重不良事件发生。截至最后一次随访，6名患者存活，44死了4人失去了随访。
■我们的研究结果表明，经导管动脉灌注化疗联合碘油化疗栓塞治疗晚期结直肠癌合并梗阻是安全有效的。它可能作为晚期结直肠癌合并梗阻患者的一种新的治疗策略。
■这项回顾性分析是使用在我们中心接受动脉灌注化疗联合碘油化疗栓塞治疗的晚期结直肠癌患者的临床资料进行的。根据无梗阻生存期和总生存期评估治疗效果，监测治疗并发症。
■纳入54例结直肠癌合并梗阻患者。所有患者均成功行经导管动脉灌注联合碘油化疗栓塞治疗。给予的平均碘油剂量为2.62±1.45ml(0.5-5.5ml)。无穿孔、肿瘤播散等严重并发症发生。临床成功率为83.3%(45/54)。治疗后一个月，客观有效率(ORR)和疾病控制率(DCR)分别为66.67%和88.9%,分别。中位无梗阻生存期为5.0个月。无严重不良事件发生。截至最后一次随访，6名患者存活，44死了4人失去了随访。
■我们的研究结果表明，经导管动脉灌注化疗联合碘油化疗栓塞治疗晚期结直肠癌合并梗阻是安全有效的。它可能作为晚期结直肠癌合并梗阻患者的一种新的治疗策略。
